ReviewCurrent pharmaceutical design2026
Insights into the Recent Breakthroughs in Nanotechnological Outlook of Pentacyclic Triterpenoids: An Updated Approach.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pentacyclic triterpenes have attracted significant scientific interest due to their notable biological activities against inflammation, cancer, liver diseases, oxidative stress, and bacterial infections. They are commonly found in fruits and vegetables and are marketed globally as nutritional supplements. Examples of pentacyclic triterpenoids include ursolic acid, oleanolic acid, boswellic acid, lupeol, betulinic acid, maslinic acid, and asiatic acid. The low water solubility, poor permeability, and limited bioavailability of pentacyclic triterpenoids hinder their therapeutic potential. The development of nanoformulations has the potential to address these limitations by facilitating effective distribution and improving therapeutic efficacy. This review provides a thorough discussion of the sources, biological activities, and mechanisms of action of pentacyclic triterpenoids. It also offers a comprehensive analysis of their integration with nanotechnological systems, including solid lipid nanoparticles, liposomes, dendrimers, polymeric micelles, silver nanoparticles, gold nanoparticles, chitosan nanoparticles, and nanostructured lipid carriers. The databases PubMed, Google Scholar, and ScienceDirect were carefully examined for relevant information. A comprehensive literature search was conducted using peer-reviewed articles published between 2000 and 2025. Review and research articles containing adequate scientific detail were included, while documents written in languages other than English were excluded. Published patents related to nanoformulations of pentacyclic triterpenoids are also briefly summarized. The clinical applications of pentacyclic triterpenoids currently in various clinical phases are outlined as well.
Indexed as
Identifiers
41837596What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.